Neptune Medical

Neptune Medical

At-home fertility diagnostics and non-invasive device

Overview

Neptune Medical develops devices and tests to address male infertility. Its two main products are Pro-Test, an at-home diagnostic kit that lets individuals test fertility parameters from home, and Neptune, a non-invasive device designed to improve sperm quality. Pro-Test provides a convenient way to assess fertility without clinic visits, while Neptune uses a proprietary, non-invasive method to enhance key sperm metrics and is intended for home use alongside clinical fertility treatment. The company serves both clinics (B2B) and individual consumers (B2C) and markets its products to help diagnose and treat male infertility, a factor in about half of all infertility cases. Neptune Medical differentiates itself by offering integrated, consumer-accessible diagnostics and treatment tools, backed by grant funding and participation in precision medicine programs, aiming to make diagnosis and treatment more private, accessible, and effective.

About Neptune Medical

Simplify's Rating
Why Neptune Medical is rated
C+
Rated C on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Healthcare

Consumer Goods

Company Size

1-10

Company Stage

Series D

Total Funding

$97M

Headquarters

Burlingame, California

Founded

2016

Get referred to Neptune Medical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 2026 Triton CARE 1 reported no adverse events and 100% cecal intubation.
  • Pathfinder's growing hospital base generates real-world evidence and commercial pull.
  • August 2024's $97 million Series D finances commercialization and clinical validation.

What critics are saying

  • Triton remains investigational in 2026; FDA clearance can slip beyond 2027.
  • Medtronic, Olympus, and colonoscopy incumbents can outspend Neptune on trials and distribution.
  • If Pathfinder adoption slows, Neptune becomes a one-product company reliant on venture capital.

What makes Neptune Medical unique

  • Pathfinder became Neptune's first FDA-cleared product, used in 15,000 patients by 2026.
  • Triton's Dynamic Rigidization targets full-colon robotic control with AI-assisted detection.
  • Neptune pairs endoscope access, robotic colonoscopy, and endovascular spinouts under one platform.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$97M

Above

Industry Average

Funded Over

0 Rounds

Benefits

401(k) Company Match

Company Equity

Company News

The Robot Report
Oct 4th, 2024
Robotics Investments Near $1B In August

Listen to this articleSwiss-Mile raised $22M in August 2024 for its wheeled quadruped. Fifty producers of robots and robotics enabling technologies received funding in August 2024, pulling in a total of approximately $1 billion. This figure is on par with the $1.2 billion average The Robot Report has tracked each of the previous 12 months. Investment targeted to robotics companies for the first eight months of 2024 equals about $10.86 billion. You can follow The Robot Report‘s investment section here. The largest investments in August were secured by developers of autonomous driving technologies

Business Wire
Aug 17th, 2024
Neptune Medical Announces $97M Series D Financing and Spinout of Jupiter Endovascular

Neptune Medical announces $97 million in Series D financing, along with the spinout of its Jupiter Endovascular subsidiary.

Recently Posted Jobs

Sign up to get curated job recommendations

Neptune Medical is Hiring for 10 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →